Mr. Speaker, in fact I was talking about pre-market work around pharmaceuticals, not natural health products.
When I was talking about natural health products, again I want to point to the concerns that were raised by the Canadian Health Food Association when it talked about the fact that the bill does not indicate any parameters and definitions, particularly around natural health products.
Part of what we have talked about in other contexts, aboriginal for example, is that if there is sufficient consultation done prior to a bill coming before the House, the passage of the bill is much smoother. In the area of natural health products, it would be very important to do appropriate consultation with not only people who manufacture the product but the users and many of our constituents who have a lot of knowledge about these products.
I would suggest that before we take a look at the risk benefit analysis for natural health products, we need to talk to the people involved in the industry in a much more thorough way.